Varsha Rathore | Cancer Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathore’s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-β signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumor–immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289–300.

Luminita Paraoan | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Luminita Paraoan | Cancer Cell Biology | Best Researcher Award

Manchester Metropolitan University | United Kingdom

Professor Luminita Paraoan is a leading molecular and ocular cell biologist whose research focuses on the molecular mechanisms underlying retinal pigment epithelium (RPE) function, degeneration, and age-related macular degeneration (AMD). Her pioneering work integrates omics-based analyses, molecular genetics, and cell biology to uncover how cellular stress responses, proteostasis, and intercellular communication contribute to retinal aging and disease. Paraoan has made significant discoveries on endoplasmic reticulum (ER) stress pathways, particularly the PERK/EIF2AK3 axis, and the regulation of apoptosis, oxidative stress, and autophagy in RPE cells. Her studies have also revealed novel insights into p53/p63 effector PERP, Cystatin C, and visual cycle gene regulation in aging and disease contexts. Through collaborative research, she has explored stem cell protection mechanisms, PI3K/AKT signaling inhibition, and multi-omic signatures of aging across cancers and ocular tissues. Supported by over £4 million in external funding, her work has advanced understanding of molecular targets for retinal and neurodegenerative diseases. Professor Paraoan leads the Ocular Molecular Biology and Mechanisms of Disease Group, mentoring numerous postdoctoral and doctoral researchers internationally, and continues to shape the field of vision science and molecular ophthalmology.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Suwanmanee, G., Kheolamai, P., Tantrawatpan, C., Grimes, D., Matei, I. V., Paraoan, L., & Manochantr, S. (2025). Fucoxanthin protects placenta-derived human mesenchymal stem cells against oxidative stress-induced apoptosis by modulating genes involved in DNA damage repair, ER stress response, and p53-induced apoptosis. Stem Cell Research & Therapy, 16(1), 497.

Jantalika, T., Manochantr, S., Kheolamai, P., Tantikanlayaporn, D., Pinlaor, S., Saijuntha, W., Paraoan, L., & Tantrawatpan, C. (2025). Human chorion and placental mesenchymal stem cells conditioned media suppress cell migration and invasion by inhibiting the PI3K/AKT pathway in cholangiocarcinoma. Scientific Reports, 15(1), 31472.

Matei, I. V., & Paraoan, L. (2024). Aging retinal pigmented epithelium: Omics-based insights into vision decline. Aging (Albany NY), 16(12), 10201–10202.

Carlsson, E., Sharif, U., Supharattanasitthi, W., & Paraoan, L. (2023). Analysis of wild type and variant B cystatin C interactome in retinal pigment epithelium cells reveals variant B. Cells, 12(5), 713.

Dhirachaikulpanich, D., Lagger, C., Chatsirisupachai, K., de Magalhães, J. P., & Paraoan, L. (2022). Intercellular communication analysis of the human retinal pigment epithelial and choroidal cells predicts pathways associated with aging, cellular senescence, and age-related macular degeneration. Frontiers in Aging Neuroscience, 14, 1016293.

Saptarshi, N., Porter, L. F., & Paraoan, L. (2022). PERK/EIF2AK3 integrates endoplasmic reticulum stress-induced apoptosis, oxidative stress, and autophagy responses in immortalised retinal pigment epithelial cells. Scientific Reports, 12(1), 13324.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Shiraz University of Medical Sciences ,Shiraz,Iran | Iran

Dr. Farhad Ghorbani is an esteemed Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. With over two decades of clinical and academic experience, he has significantly contributed to the fields of oral pathology, trauma, and surgical interventions. A graduate of Kerman University of Medical Sciences, Dr. Ghorbani later specialized further at Shiraz University. His dedication to advancing clinical knowledge is reflected in over a dozen high-impact peer-reviewed publications, focusing on craniofacial abnormalities, surgical outcomes, and rare oral diseases. He is an active researcher with a Scopus Author ID and ORCID, consistently contributing to scientific journals like BMC Oral Health, Scientific Reports, and Maxillofacial Plastic and Reconstructive Surgery. His multidisciplinary collaborations have led to enhanced diagnostic techniques and patient outcomes. Dr. Ghorbani is recognized for both his innovative research and his commitment to medical education.

Publication Profile: 

Orcid

Google Scholar

Education:

Dr. Ghorbani began his medical journey at Kerman University of Medical Sciences, earning his professional doctorate in dentistry (1992–1998). Following years of clinical practice, he advanced his academic and surgical expertise by joining Shiraz University of Medical Sciences in 2013, where he underwent specialized training in Oral and Maxillofacial Surgery and served as an Assistant Professor during his educational tenure (2013–2018). His academic training focused on maxillofacial pathology, surgical techniques, and interdisciplinary diagnostics. The combination of strong foundational medical education and advanced surgical specialization has equipped him with both the theoretical depth and clinical acumen to lead impactful research. His training underlines a commitment to academic excellence and lifelong learning, which is further reflected in his scholarly contributions. Dr. Ghorbani’s educational background bridges foundational dental sciences with advanced surgical innovation.

Experience:

Since December 2018, Dr. Farhad Ghorbani has held the position of Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. His career blends clinical practice, research, and teaching. Over the years, he has led numerous studies exploring craniofacial morphology, surgical outcomes, dental trauma, and maxillofacial pathologies. He mentors postgraduate students and collaborates with interdisciplinary teams, enhancing diagnostic accuracy and surgical care. His work in both rural and urban settings has exposed him to a wide spectrum of maxillofacial cases, enriching his clinical insights. He actively contributes to improving surgical protocols and patient care standards. Dr. Ghorbani’s experience also includes academic publishing, peer reviews, and participation in scientific forums. He is recognized for his analytical approach and evidence-based practice. His long-standing affiliation with reputed institutions and research groups underscores his strong leadership in oral surgery and academic scholarship.

Research Focus:

Dr. Ghorbani’s primary research interests lie in oral pathology, craniofacial surgery, dentoalveolar trauma, and radiological diagnostics. His work often combines clinical case reports with retrospective analysis, offering insights into rare presentations such as parathyroid carcinoma-linked jaw tumors, and developmental anomalies like concha bullosa. A hallmark of his research is his ability to identify atypical symptoms and connect them with broader systemic conditions, ensuring early diagnosis and management. He has conducted fractal analysis studies to evaluate bone quality, and he explores patient-centered outcomes, such as satisfaction post-rhinoplasty and the psychological impacts of facial surgery. Additionally, his research evaluates the intersection of dental surgery with systemic health—evident in studies related to auditory changes post-orthognathic surgery or the implications of COVID-19 on dental care. Through evidence-based methods and innovative case analyses, Dr. Ghorbani has positioned himself as a thought leader in interdisciplinary oral and maxillofacial research.

Publications Top Notes:

  1. Brown tumors of both jaws as the initial manifestation of parathyroid carcinoma (BMC Oral Health, 2025)

  2. Distribution and laterality of concha bullosa across cranial skeletal types (Maxillofacial Plastic Surg, 2025)

  3. Calcifying Odontogenic Cyst in Posterior Maxilla: A Case Report (Journal of Dentistry Shiraz, 2025)

  4. Central giant cell granuloma mimicking fibro-osseous lesion and hemangioma (J Med Case Reports, 2024)

  5. Fractal CT analysis of mandibular condyles in class III malocclusion (Scientific Reports, 2023)

  6. Patient dissatisfaction following rhinoplasty: A 10-year Iranian study (Maxillofacial Plastic Surg, 2023)

  7. Correlation between impacted third molar and blood group (Int J of Dentistry, 2021)

  8. Effects of orthognathic surgery on auditory function (Maxillofacial Plastic Surg, 2021)

  9. Evaluation of alveolar fractures in trauma patients in Iran (BMC Oral Health, 2021)

  10. Anxiety in patients undergoing mandibular third molar extraction (J Oral Research & Review, 2020)

Conclusion:

In summary, Dr. Farhad Ghorbani embodies the qualities of a deeply committed, analytically skilled, and academically active oral and maxillofacial surgeon. His research is directly informed by his clinical experience, allowing him to bridge theory and practice effectively. His contributions have enriched the literature on oral pathology, surgical complications, facial aesthetics, and patient psychology following treatment interventions. While there are opportunities to expand the scope and scale of his work through more robust methodologies and international collaboration, his existing portfolio already reflects a high standard of academic and clinical integration. Given his track record, ongoing research productivity, and evident commitment to innovation and education, Dr. Ghorbani is a strong and deserving candidate for the Best Researcher Award. With continued growth in research leadership and expanded global outreach, he is poised to make an even greater impact in the years ahead.

HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Dr. HEMAMALINI MADHUKAR, Mother Teresa Women’s University, India

Dr. Madhukar Hemamalini is an accomplished Assistant Professor in the Department of Chemistry at Mother Teresa Women’s University, Kodaikanal. With over five and a half years of dedicated research experience and eight years of teaching, she has made significant contributions to the field of structural and bioorganic chemistry. Her expertise lies in X-ray crystallography, protein-ligand interactions, and the synthesis of supramolecular and pharmaceutical compounds. She earned her Ph.D. in Chemistry from Bharathidasan University and completed a postdoctoral fellowship under Prof. H.-K. Fun at Universiti Sains Malaysia. With 234 international publications and a citation index reflecting her research impact, Dr. Hemamalini’s academic presence is both global and influential. Her guidance to 10 M.Phil. and 21 M.Sc. students reflects her commitment to mentoring the next generation of scientists. She actively contributes to academic committees and has led a UGC Minor Research Project on hydrogen bonding and phase transition.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Extensive Publication Record

    • Over 234 international research publications, primarily in reputed journals such as Journal of Molecular Structure, Molecular Diversity, Russian Journal of Inorganic Chemistry, and IUCrData.

    • Research themes include X-ray crystallography, drug-likeness prediction, molecular docking, and biochemical analysis.

  2. Strong Research Background

    • Postdoctoral research in crystallography at Universiti Sains Malaysia (USM) under a globally respected crystallographer, Prof. H.-K. Fun.

    • More than five and a half years of focused research experience in supramolecular and macromolecular chemistry.

  3. Citation Impact

    • Accumulated 228 citations, with a h-index of 12 and i10-index of 8, reflecting a solid impact in her field.

  4. Mentorship & Teaching

    • 8 years of teaching experience as an Assistant Professor.

    • Mentored 10 M.Phil. and 21 M.Sc. students — demonstrating her commitment to research training and knowledge dissemination.

  5. Research Funding

    • Successfully secured UGC Minor Research Project funding of ₹5,00,000 for studies on hydrogen bonding and phase transition.

  6. Academic Service

    • Contributed to institutional growth as inspection committee member for women’s colleges, affirming leadership in academic governance.

⚠️ Areas for Improvement:

  1. Enhance International Collaboration

    • Collaborations beyond Malaysia, particularly with Europe or North America, could increase citation visibility and interdisciplinary reach.

  2. Diversify Funding Sources

    • Apply for major national/international grants (e.g., DST, DBT, SERB, or industry-academic partnerships) for scaling research infrastructure and student involvement.

  3. Intellectual Property & Innovation

    • Translating research into patents, prototypes, or industry consultancies would enhance her research’s practical value and real-world impact.

  4. Public Engagement and Outreach

    • Participation in conferences as keynote speaker, science communication, or popular science articles would further establish her academic persona.

🎓 Education:

Dr. Madhukar Hemamalini completed her Ph.D. in Chemistry in October 2006 from Bharathidasan University, India, specializing in structural and supramolecular chemistry. Her doctoral research focused on the synthesis and crystallographic analysis of organic compounds, laying a strong foundation for her future work in macromolecular systems. Prior to her doctorate, she obtained her M.Sc. in Chemistry in August 2000 and B.Sc. in Chemistry in August 1998, both from Bharathidasan University. Her academic training has equipped her with a deep understanding of chemical interactions at the molecular level, especially those relevant to drug design, protein-ligand binding, and pharmaceutical solids. Her academic trajectory showcases her longstanding passion for exploring the molecular world through advanced techniques like X-ray crystallography and computational chemistry. Additionally, her exposure to interdisciplinary research at Universiti Sains Malaysia has expanded her global outlook and enriched her research methodologies.

🧪 Experience:

Dr. Hemamalini has a cumulative 13+ years of experience in academia and research. She is currently serving as Assistant Professor at the Department of Chemistry, Mother Teresa Women’s University, Kodaikanal since March 2015. Her teaching portfolio includes mentoring postgraduate and M.Phil. students, with 21 M.Sc. and 10 M.Phil. students successfully guided under her supervision. From December 2009 to February 2012, she pursued Post-Doctoral research in X-ray crystallography at Universiti Sains Malaysia under the mentorship of Prof. H.-K. Fun, focusing on supramolecular motifs and metal coordination complexes. Her total research experience spans over five and a half years, during which she explored protein-ligand interactions, crystal engineering, and bioorganic compound synthesis. She also participated in institutional academic committees and inspection boards, contributing to higher education quality assurance. Her dual expertise in both teaching and high-impact research makes her a well-rounded academic professional.

🏆 Awards and Honors:

Dr. Madhukar Hemamalini has been the recipient of the prestigious Senior Research Fellowship (SRF) from the Council of Scientific and Industrial Research (CSIR), New Delhi (2004–2006), which stands as a testimony to her research potential and academic rigor. In addition to this major national honor, she has been involved in several university-level academic panels, including Inspection Committees for women’s colleges in Dindigul, highlighting her contributions to academic governance and quality control. Her funded project under the UGC Minor Research Project Scheme—with a sanctioned amount of ₹5,00,000—focused on the hydrogen bonding interactions and phase transition studies in organic compounds, an area of current interest in molecular chemistry. Her work has been cited over 228 times, and she holds a h-index of 12 and an i10-index of 8, reflecting a consistent and meaningful research output across international journals.

🔬 Research Focus:

Dr. Hemamalini’s research revolves around X-ray crystallography, macromolecular chemistry, and supramolecular design. Her scientific interest lies in unraveling structure–function relationships in molecules, particularly in protein-ligand complexes, bioorganic frameworks, and pharmaceutical solids. She has applied her expertise in both experimental (e.g., crystal growth and structural analysis) and computational techniques (e.g., molecular docking, dynamics simulations) to synthesize novel compounds with potential drug-like behavior. Her interdisciplinary approach bridges chemistry with biology, enabling her to work on problems like TNF-α inhibition in rheumatoid arthritis, anti-cancer screening, and antidiabetic compound design. She has actively published in reputed journals, showcasing both synthetic and theoretical studies. Her postdoctoral training at Universiti Sains Malaysia helped her master crystallographic techniques, further enriching her analytical capabilities. Her work continues to contribute valuable insights into biomolecular recognition, drug-receptor modeling, and material science.

📚 Publications Top Notes: 

  1. 📄 Synthesis of 3-Methoxy…phenol Schiff base: spectral, in-silico & in-vitro studies – Heliyon, 2022

  2. 🧬 In silico and in vitro identification of TNF-α inhibitors from Euphorbia hirta for rheumatoid arthritis – Molecular Diversity, 2025

  3. 💊 Anti-diabetic activity of pyrimidinium-hydrogen oxalate conjugates: synthesis, docking & simulation – Journal of Molecular Structure, 2025

  4. 🧪 [2-(1H-indol-3-yl)ethyl]-(4-nitrobenzylidene)amine: anti-breast cancer & antibacterial insights – Journal of Molecular Structure, 2025

  5. 🔬 PPI networking, expression analysis & TNF-α inhibitor screening for RA – Molecular Diversity, 2025

  6. 🧫 6-Bromo-9,9-diethyl-N,N-diphenylfluoren-2-amine – Data Paper

  7. 🧊 Insights into oxidovanadium porphyrin: synthesis & Hirshfeld surface analysis – Journal of Molecular Structure, 2024

  8. 🧬 1,4-Dimethylpiperazine-2,3-dione – crystal structure study – Iucrdata, 2024

  9. ⚗️ (1H-Benzodiazol-2-ylmethyl)diethylamine – molecular characterization – Iucrdata, 2024

  10. 🔍 Structural & oxidative studies of (3,4,5-trimethoxyphenyl)Porphyrin Ni(II) Complex – Russian Journal of Inorganic Chemistry, 2024

🧾 Conclusion:

Dr. Madhukar Hemamalini possesses a well-rounded academic profile with consistent research output, teaching excellence, mentorship, and academic service. Her work in structural and medicinal chemistry, particularly involving crystallography and biomolecular interactions, has practical implications in drug discovery and material science. She demonstrates all the key markers of a successful and impactful researcher.

HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Prof. Dr. WAN-JEONG JEONG , Department of Nuclear Medicine, Molecular Imaging Therapeutic Medicine Research Center, Jeonbuk Regional Cyclotron Research Center & Biotracer Imaging Lab. Jeonbuk National University Medical School & Hospital, South Korea

Dr. Hwan-Jeong Jeong is a distinguished leader in the field of nuclear medicine, currently serving as Director and Professor at Jeonbuk National University Medical School & Hospital, South Korea. With over two decades of academic and clinical experience, Dr. Jeong has pioneered research in molecular imaging, photobiomodulation, and radiopharmaceutical science. He has made impactful contributions to translational oncology, neuroimaging, and light-based therapeutics. With over 120 peer-reviewed publications, 33 patents, and an H-index of 44, his work bridges the gap between basic science and clinical innovation. Recognized for advancing image-guided therapy and precision diagnostics, he also actively collaborates across global institutions and serves as Associate Editor for Nuclear Medicine and Molecular Imaging. A recipient of multiple national and international recognitions, Dr. Jeong’s efforts continue to shape the future of medical imaging and cancer therapeutics. His commitment to integrating engineering and medicine marks him as a global innovator in nuclear and molecular medicine.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Outstanding Academic and Clinical Background: Dr. Jeong holds an MD, a Master’s in Medical Engineering, and a PhD in Medicine, with postdoctoral training at the prestigious MD Anderson Cancer Center.

  • Leadership in Research: As Director of multiple research centers, he has led over 20 high-impact projects, overseen 5 industry collaborations, and contributed to 120+ SCI-indexed publications.

  • Innovation & Translation: Holder of 33 patents, Dr. Jeong is a pioneer in integrating photobiogoverning, PET/CT imaging, and light-based cancer therapy, bridging lab discoveries and clinical application.

  • Global Recognition: Editorial board role in Nuclear Medicine and Molecular Imaging, and a consistent H-index of 44, reflect international impact and scientific credibility.

  • Cutting-Edge Contributions: Known for novel developments in blue light phototherapy, tumor-targeted radiopharmaceuticals, and noninvasive neuroimaging, significantly advancing cancer and neurological diagnostics.

⚠️ Areas for Improvement:

  • Broader International Collaboration: While highly respected in Korea and internationally, formalizing more international co-research programs or multicenter trials could further expand global reach.

  • Public Engagement & Science Communication: Increasing public visibility through science outreach, open-access publications, or global lectures/webinars can elevate the societal impact of his research.

  • Interdisciplinary Expansion: Potential to integrate AI-based imaging analysis or bioinformatics tools into existing molecular imaging and diagnostics research may boost next-gen innovation.

🎓 Education:

Dr. Hwan-Jeong Jeong began his academic journey at Chonnam National University, where he earned his MD in 1993, followed by a Master’s in Medical Engineering in 2000, and a Ph.D. in Medicine in 2003. He pursued his residency in Nuclear Medicine at Chonnam National University Hospital, gaining a strong clinical foundation. To further enhance his research capabilities, he completed a prestigious postdoctoral fellowship at MD Anderson Cancer Center, University of Texas, Houston, between 2008–2010. His educational path reflects an interdisciplinary approach—blending clinical medicine, biomedical engineering, and advanced imaging sciences. With an emphasis on nuclear medicine and optical diagnostics, Dr. Jeong’s educational background has strategically positioned him at the intersection of clinical practice and high-impact research. His academic evolution reflects a consistent dedication to innovation, translational research, and global collaboration.

🧪 Experience:

Dr. Jeong has served as Director and Professor of Nuclear Medicine at Jeonbuk National University Medical School & Hospital since 2005. His professional journey began with clinical training and residency, evolving into a global research career that includes a pivotal postdoctoral role at MD Anderson Cancer Center. Over the years, he has directed more than 20 research projects, consulted on 5 industry collaborations, and published over 120 scientific papers. Dr. Jeong holds 33 patents, highlighting his innovation in photomedicine and molecular imaging. He leads multiple advanced imaging centers and research labs, including the Molecular Imaging Therapeutic Medicine Research Center and Jeonbuk Regional Cyclotron Research Center. Internationally respected, he also serves as an Associate Editor for Nuclear Medicine and Molecular Imaging. His experience combines clinical expertise, leadership in research infrastructure, and international collaborations that foster innovation and patient-centered imaging solutions.

🔬 Research Focus:

Dr. Jeong’s research lies at the nexus of nuclear medicine, molecular imaging, and photobiomodulation therapy. His groundbreaking work integrates blue light phototherapy, PET/CT molecular imaging, radiopharmaceutical development, and fiber-optic–guided treatment systems for cancers and neurological disorders. He has made significant advances in FDG-PET imaging, amyloid brain scans, and light-triggered tumor therapies, facilitating precision diagnostics and targeted interventions. A key innovator in photobiogoverning—the biological control via light—Dr. Jeong has translated preclinical concepts into clinical applications through rigorous trials and device validation. His projects often explore the interface between biomedical optics and nano-diagnostics, enhancing real-time monitoring and minimally invasive treatments. Through cross-disciplinary collaborations and cutting-edge device design, he has shaped protocols that merge imaging with therapy for high-impact patient outcomes. His research aligns closely with future directions in personalized medicine and oncology imaging.

📚 Publications Top Notes:

  • 📘 From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment

  • 📘 Blue-light activated nanoplatforms for image-guided cancer therapy

  • 📘 Clinical applications of brain amyloid PET imaging in neurodegenerative diseases

  • 📘 Multimodal theranostics using PET/CT and photodynamic therapy in head and neck cancer

  • 📘 Innovative radiotracers for monitoring tumor hypoxia and therapeutic response

  • 📘 Fiber-optic–based interstitial phototherapy in liver malignancies: A pilot clinical study

  • 📘 Nanomedicine-based nuclear imaging in virus-infected tissues

  • 📘 Bioluminescent imaging in evaluating immunotherapy response in solid tumors

  • 📘 Therapeutic implications of photobiogoverning in minimally invasive oncology

  • 📘 Noninvasive tracking of neuroinflammation using fluorinated PET probes

🧾 Conclusion:

Dr. Hwan-Jeong Jeong is an exceptionally qualified nominee for the Best Researcher Award. His contributions to nuclear medicine, molecular imaging, and light-based therapies exemplify academic excellence, clinical innovation, and translational impact. His body of work aligns closely with the award’s values—scientific rigor, real-world application, and forward-thinking medical solutions. With ongoing work in precision diagnostics and phototherapy, he not only meets but exceeds the standards expected of top global researchers in biomedical science. Dr. Jeong’s profile is a model of interdisciplinary leadership, making him a compelling and well-deserved recipient for this prestigious recognition.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions 📚 – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise 🏥 – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants 💰 – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions 🏆 – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

📌 Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

🎓 Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

💼 Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

🏆 Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai 🏅

  • Shanghai Medical Leading Talent 🎖️

  • Shanghai Craftsman & Shanghai Medical Craftsman 🏆

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

🔬 Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

📚 Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel 🔬🧬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy 🏥🧪

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway 🏥💊

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer 🔎⚕️

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus 🏥🔬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma 💉🔬

  7. Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men 🧬🧑‍⚕️

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer 🩸🛡️

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma 🏥📊

🏅 Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. 🚀